Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05872152

Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs

Impact of Fourier Transform Infrared Spectroscopy (FTIRS) on the Diffusion of ESBL Producing Enterobacterales in Intensive Care Units (ICU)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
900 (estimated)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

This study will assess the impact of FTIRS typing on the spread of ESBL-E in intensive care units

Detailed description

Multidrug resistant enterobacterales (MDR-E) are a major threat for patients hospitalized in intensive care units (ICUs). To prevent MDR-E spread in ICUs, rectal swabs are routinely performed and cultured on selective media. However, bacterial identification and antimicrobial susceptibility results are not sufficient to diagnose cross transmissions. The gold standard technique is based on genomic analysis that require whole genome sequencing (WGS) of bacteria and followed by multilocus sequence typing (MLST) and Single Nucleotide Polymorphism (SNP) typing. This technology is rather expensive and not applicable in all centers. Fourier Transform InfraRed Spectroscopy (FTIRS) is a developing method for rapid bacterial typing. This technology is simple and results can be obtained in one hour. It is therefore adapted to continuous surveillance of MDR-E. In France, extended spectrum betalactamase producing enterobacteriaceae (ESBL-E) represent the vast majority of MDR-E. We postulate that early diagnosis of cross-transmission by FTIRS may prevent the spread of ESBL-E in ICUs and favor compliance with hygiene measures. The aim of this study will be to assess the impact of systematic FTIRS typing of ESBL-E on ESBL-E cross-transmissions in ICUs.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTFTIR resultsWeekly transmission of FTIRS typing of ESBL-E to centers

Timeline

Start date
2024-01-08
Primary completion
2026-09-01
Completion
2026-09-01
First posted
2023-05-24
Last updated
2025-07-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05872152. Inclusion in this directory is not an endorsement.